Personalized vaccine takes aim at recurrent brain tumors
NCT ID NCT07678138
First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time
Summary
This trial tests a personalized vaccine called YS247 for people with recurrent glioblastoma, an aggressive brain cancer. The vaccine is made from each patient's own immune cells and designed to target unique markers on their tumor. The study aims to see if the vaccine is safe and tolerable, and to get an early look at whether it can help control the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tumor neoantigen-pulsed autologous dendritic cell injection (YS247)
- What this could lead to
- If it works, this could point toward a new treatment option for recurrent glioblastoma, a brain cancer with few effective therapies.
- What could go wrong
- This is a very early, small trial with only 9 participants, so results may not apply broadly. The vaccine is personalized and complex, and side effects or lack of benefit are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New imaging clues could sharpen brain tumor monitoring
- Can a virus injected into brain tumors fight recurrence?
- Can a Tumor's genetic blueprint guide better treatment for kids with brain cancer?
- Can a seizure drug outsmart a deadly brain tumor?
- A simple lotion duo may shield skin from Tumor-Treating fields
- Can a One-Two punch slow recurrent brain cancer?